Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Deloitte
US Army
Queensland Health
Johnson and Johnson
Covington
Cantor Fitzgerald
Daiichi Sankyo
Dow
McKesson

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,544,713

« Back to Dashboard

Summary for Patent: 7,544,713
Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: ##STR00001##
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:11/603,116
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,544,713

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-001 Dec 20, 2013 RX Yes No ➤ Sign Up ➤ Sign Up USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). ➤ Sign Up
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-002 Dec 20, 2013 RX Yes No ➤ Sign Up ➤ Sign Up USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). ➤ Sign Up
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-003 Dec 20, 2013 RX Yes No ➤ Sign Up ➤ Sign Up USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). ➤ Sign Up
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-004 Dec 20, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). ➤ Sign Up
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-005 Oct 7, 2016 RX Yes No ➤ Sign Up ➤ Sign Up USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,544,713

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,384,978 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
8,252,839 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
9,278,901 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
8,410,169 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
9,050,311 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
9,422,223 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
9,199,908 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
8,536,363 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
7,417,070 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
9,878,972 Compounds and methods for delivery of prostacyclin analogs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,544,713

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2526534 ➤ Sign Up
Canada 2736406 ➤ Sign Up
Canada 2851309 ➤ Sign Up
Canada 2959852 ➤ Sign Up
China 100558351 ➤ Sign Up
China 101265226 ➤ Sign Up
China 101780092 ➤ Sign Up
China 102697790 ➤ Sign Up
China 1822826 ➤ Sign Up
European Patent Office 1628654 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cerilliant
QuintilesIMS
Johnson and Johnson
Moodys
Argus Health
McKesson
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot